Martin Nicklasson - BioInvent International Director
| BINV Stock | SEK 23.95 2.45 11.40% |
Director
Mr. Martin Nicklasson was Director of BioInvent International Aktiebolag since My 12, 2016. He is also Associate Professor at the Faculty of Pharmacy, Uppsala University. He is Former CEO of Swedish Orphan Biovitrum AB 20072010. He also held several positions with AstraAstraZeneca, including responsible for global drug development and marketing and business development with AstraZeneca Ltd., and CEO of AstraZeneca Sweden AB. He was CEO of Astra Hassle AB and responsible for RD within KABI. He is Pharmacist and holds Decorate of Philosophy degree. He is Chairman of the Board of Orexo AB, Zealand Pharma AS and Farma Investment AS as well as Member of the Boards of Basilea Pharmaceutical Ltd., PledPharma AB, Premier Research Group Ltd and Biocrine AB. since 2016.
| Age | 60 |
| Tenure | 8 years |
| Phone | 46 4 62 86 85 50 |
| Web | https://www.bioinvent.com |
BioInvent International Management Efficiency
The company has return on total asset (ROA) of (0.0192) % which means that it has lost $0.0192 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.0274) %, meaning that it generated substantial loss on money invested by shareholders. BioInvent International's management efficiency ratios could be used to measure how well BioInvent International manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 6 records | DIRECTOR Age | ||
| Mariel Clemensen | Anoto Group AB | N/A | |
| Perry Ha | Anoto Group AB | N/A | |
| Henric Ankarcrona | Anoto Group AB | 70 | |
| Jeff Weedman | Anoto Group AB | N/A | |
| Henrik Hammarskiold | Anoto Group AB | N/A | |
| DongYi Lee | Anoto Group AB | N/A | |
Management Performance
| Return On Equity | -0.0274 | |||
| Return On Asset | -0.0192 |
BioInvent International Leadership Team
Elected by the shareholders, the BioInvent International's board of directors comprises two types of representatives: BioInvent International inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioInvent. The board's role is to monitor BioInvent International's management team and ensure that shareholders' interests are well served. BioInvent International's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioInvent International's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andres McAllister, Chief Medical Officer | ||
| Trevor Juniper, Senior Vice President Corporate Development | ||
| Jonas Jendi, Director | ||
| Lars Ingelmark, Independent Member of the Board of Directors | ||
| Martin Nicklasson, Director | ||
| Niklas Prager, Director | ||
| Kristoffer Hansson, Vice President Technical Operations | ||
| Dharminder Chahal, Director | ||
| Vessela Alexieva, Director, Employee Representative | ||
| Kristoffer Bissessar, Director | ||
| RGN MSc, Chief Officer | ||
| Elin Gyllenback, Director, Employee Representative | ||
| Elisabeth Lindner, Independent Member of the Board of Directors | ||
| Michael Oredsson, President CEO | ||
| PerAnders Johansson, Senior Vice President Technical Operations | ||
| Martin Welschof, President CEO | ||
| Ingrid Teige, Head Research | ||
| Bjorn Frendeus, Vice President for Preclinical Research | ||
| Vincent Ossipow, Director | ||
| Bjrn Frendus, Chief Officer | ||
| Bjorn Nilsson, Independent Chairman of the Board of Directors | ||
| Bernd Seizinger, Director | ||
| Stefan MBA, Chief Officer | ||
| Birgitta Goransson, Director | ||
| An Johansson, Director | ||
| Leonard Kruimer, Director | ||
| Cecilia Hofvander, Director Relations | ||
| Ulrika Mattson, Member of the Board of Directors, Employee Representative | ||
| Anna Wickenberg, VP of Clinical Devel. | ||
| Stefan Ericsson, CFO | ||
| Sylvie Ryckebusch, Chief Officer |
BioInvent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioInvent International a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0274 | |||
| Return On Asset | -0.0192 | |||
| Profit Margin | (0.14) % | |||
| Operating Margin | (0.16) % | |||
| Current Valuation | 1.16 B | |||
| Shares Outstanding | 65.8 M | |||
| Shares Owned By Insiders | 11.10 % | |||
| Shares Owned By Institutions | 57.02 % | |||
| Price To Earning | (9.49) X | |||
| Price To Book | 1.40 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards BioInvent International in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, BioInvent International's short interest history, or implied volatility extrapolated from BioInvent International options trading.
Pair Trading with BioInvent International
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioInvent International position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioInvent International will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to BioInvent International could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioInvent International when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioInvent International - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioInvent International AB to buy it.
The correlation of BioInvent International is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioInvent International moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioInvent International moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioInvent International can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioInvent International AB. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Complementary Tools for BioInvent Stock analysis
When running BioInvent International's price analysis, check to measure BioInvent International's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioInvent International is operating at the current time. Most of BioInvent International's value examination focuses on studying past and present price action to predict the probability of BioInvent International's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioInvent International's price. Additionally, you may evaluate how the addition of BioInvent International to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |